LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 84% planned / 16% discretionary
Largest single sale: $9.2M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Reardon Andrew 5 fills | CLO & Secretary | Sell 10b5-1 | 5,000 | $286.09 | $1.4M | 41,214 −10.8% of holding | |
| Espinoza Octavio | Chief Financial Officer | Sell 10b5-1 | 31,641 | $292.06 | $9.2M | 27,696 −53.3% of holding | |
| Haas Jason | Director | Sell | 7,138 | $292.81 | $2.1M | 3,981 −64.2% of holding | |
| Reardon Andrew 10 fills | CLO & Secretary | Sell 10b5-1 | 5,000 | $288.99 | $1.4M | 46,409 −9.7% of holding | |
| Reardon Andrew 8 fills | CLO & Secretary | Sell 10b5-1 | 5,000 | $313.28 | $1.6M | 46,118 −9.8% of holding | |
| Sabba Stephen L | Director | Sell | 2,145 | $254.00 | $544.8K | 33,629 −6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.